PARP Inhibitors: Staying on Target?
نویسندگان
چکیده
منابع مشابه
PARP inhibitors
Poly (ADP-ribose) polymerases, abbreviated as PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular ac...
متن کاملPARP Inhibitors
Poly (ADP-ribose) polymerase (PARP) is a novel therapeutic target in cancer. Preclinical studies demonstrate that PARP inhibitors selectively kill BRCAdeficient cells and potentiate the effects of DNA-damaging agents. There are several PARP inhibitors in clinical development, including olaparib, iniparib, veliparib, PF01367338, and MK-4827. Phase II studies of single-agent olaparib demonstrate ...
متن کاملStaying on target with continuous dialysis.
“It was through the evolution of this filtrationreabsorption system that the kidney came to be almost entirely responsible for the composition of the internal environment of the body,manufacturing it, as we have said, in reverse, by saving some things from the glomerular filtrate and rejecting others. Among the substances known to be reabsorbed by the tubules in man, for example, are water, sod...
متن کاملPARP inhibitors and more.
Polyadenosine diphosphate (ADP) ribose polymerase (PARP) lends a panoramic view to the inner mystery of protection of integrity of deoxyribonucleic acid (DNA) in a cell genome. They are a balancing part of an even more dynamic equilibrium of normalcy against daily assaults. PARP finds its companion candidates in other tumor suppressors, with the most prominent and glaring one being breast cance...
متن کاملPARP inhibitors in breast cancer.
The therapeutic implications of DNA damage in cancer therapy have long been appreciated and form the basis of many successful cytotoxic chemotherapy and radiotherapy treatment strategies. A novel class of DNA repair defect targeted therapeutics that inhibit poly (ADP-Ribose) polymerase (PARP) are being rapidly developed in breast cancer based on exciting preliminary clinical activity as single ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cell Chemical Biology
سال: 2016
ISSN: 2451-9456
DOI: 10.1016/j.chembiol.2016.12.003